The fundraise will help advance a cancer therapy that’s already shown early promise in people whose cancers haven’t responded ...

The FDA had halted use in older adults while it investigated reports of side effects. The vaccine’s label now carries new ...

While orforglipron succeeded in a Phase 3 trial, its weight loss effects were more modest than investors and analysts ...

The initiative is a response to a Trump administration order to speed the construction of the type of new drug factories many pharmaceutical companies have promised to build.

The company hopes an important CVS deal and broader legal action against the makers of knockoff Wegovy can solidify its ...

The biotech industry needs to be supported by the government, by Congress,” Pfizer’s Albert Bourla told investors Tuesday in ...

The company formerly known a Sosei Heptares unveiled new weight loss programs. Elsewhere, BridgeBio and Madrigal unveiled ...

The investment, which the foundation says is its largest in women’s health, will support research in maternal health, ...

A potentially billion-dollar acquisition of Gilgamesh Pharmaceuticals suggests big pharma may finally be willing to place ...

Pfizer's Albert Bourla told investors that major drugmakers are "ready to roll up their sleeves" and build out more direct-to ...

Frazier was among the most active venture investors in 2024, according to analysts at William Blair, backing 17 private life ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives and advance five ...